華潤醫藥(03320.HK)高血壓藥獲藥監局頒發補充批件
華潤醫藥(03320.HK)公布,旗下華潤賽科的苯磺酸氨氯地平片(2.5mg)獲國家藥監局頒發《藥品補充申請批件》,可對苯磺酸氨氯地平片規格作進一步補充,料將有利於發揮該藥品未來市場銷售和市場競爭力。
該苯磺酸氨氯地平片主要用於治療高血壓及冠心病,原研為 2.5mg、5mg、10mg 三個規格。華潤賽科已
於2011年獲批5mg規格並於2018年7月24日通過一致性評價。為滿足不同患者人群的用藥需求,華潤賽科自2018年8月啟動增加2.5mg規格的補充研究工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.